---
title: "ApicHope Pharmaceutical Group Co.,Ltd (300723.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300723.SZ.md"
symbol: "300723.SZ"
name: "ApicHope Pharmaceutical Group Co.,Ltd"
industry: "Pharmaceuticals"
datetime: "2026-05-21T23:16:51.909Z"
locales:
  - [en](https://longbridge.com/en/quote/300723.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300723.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300723.SZ.md)
---

# ApicHope Pharmaceutical Group Co.,Ltd (300723.SZ)

## Company Overview

ApicHope Pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of pharmaceutical drugs in China. The company offers pediatric medicines, such as fuganlin and yiqi jianpi oral liquids, carboxymestrine oral solutions, and xiao’er kechuanling oral liquid products; and clindamycin palmitate hydrochloride dispersible tablets, acetylkitasamycin for suspension, qinxiangqingjie oral liquids, epinastine hydrochloride granules, clindamycin palmitate hydrochloride granules, clindamyxin hydrochloride for injection, clindamycin phosphate injection, ambroxol hydrochloride drops, montelukast sodium oral granules, oseltamivir phosphate capsules, and levocetirizine dihydrochloride oral drops. It also provides chronic disease drugs, including aciclovir for injection, hepatocyte growth-promoting factor for injection, pentoxifylline injection, kangshen and niaoqingshu granules, shenbo lotion, compound monoammonium glycyrrhizinate s and lansoprazole for injection, omeprazole sodium for injection, and other products.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.apichope.com](https://www.apichope.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:13.000Z

**Overall: D (0.62)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 180 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -21.88% |  |
| Net Profit YoY | 134.25% |  |
| P/B Ratio | 8.91 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 17212476813.62 |  |
| Revenue | 938969104.39 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 10.33% | B |
| Profit Margin | 21.26% | A |
| Gross Margin | 66.08% | A |
| Revenue YoY | -21.88% | E |
| Net Profit YoY | 134.25% | A |
| Total Assets YoY | -10.45% | E |
| Net Assets YoY | -0.91% | D |
| Cash Flow Margin | 13.19% | D |
| OCF YoY | -21.88% | E |
| Turnover | 0.19 | D |
| Gearing Ratio | 58.04% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - ApicHope Pharmaceutical Group Co.,Ltd",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-21.88%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "134.25%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "8.91",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "17212476813.62",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "938969104.39",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "10.33%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "21.26%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "66.08%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-21.88%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "134.25%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-10.45%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-0.91%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "13.19%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-21.88%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.19",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "58.04%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 89.89 | 135/215 | 93.62 | 90.55 | 86.91 |
| PB | 9.29 | 208/215 | 14.80 | 11.93 | 8.91 |
| PS (TTM) | 19.11 | 208/215 | 23.94 | 19.84 | 15.34 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-01-31T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 39.80 |
| Highest Target | 35.88 |
| Lowest Target | 35.88 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300723.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300723.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300723.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300723.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**